BioCentury
ARTICLE | Clinical News

Amphinex: Phase II discontinued

June 29, 2015 7:00 AM UTC

PCI Biotech discontinued the open-label, European Phase II ENHANCE trial of 0.25 mg/kg IV Amphinex followed by laser therapy. The company cited increased competition by emerging immunotherapies for th...